Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Juan Pan, Tuxiong Huang, Zhenjun Deng, Chang Zou
Recent studies have demonstrated that N6-methyladenosine (m6A), the most abundant, dynamic, and reversible epigenetic RNA modification in eukaryotes, is regulated by a series of enzymes, including methyltransferases (writers), demethylases (erasers), and m6A recognition proteins (readers). Aberrant regulation of m6A modification is pivotal for tumorigenesis, progression, invasion, metastasis, and apoptosis of malignant tumors. Immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, as recognized by the 2018 Nobel Prize in Medicine and Physiology...
2023: Frontiers in Immunology
#2
JOURNAL ARTICLE
Yueting Huang, Huijian Zheng, Yuwen Zhu, Yan Hong, Jie Zha, Zhijuan Lin, Zhifeng Li, Caiyan Wang, Zhihong Fang, Xingxing Yu, Long Liu, Bing Xu
INTRODUCTION: Despite accumulated evidence in T-cell exhaustion in acute myeloid leukemia (AML), the immunotherapeutic targeting exhausted T cells such as programmed cell death protein 1 (PD-1) blockade in AML failed to achieve satisfying efficacy. Characteristics of exhausted T cells in AML remained to be explored. METHODS: Phenotypic analysis of T cells in bone marrow (BM) using flow cytometry combining senescent and exhausted markers was performed in de novo AML patients and healthy donors as well as AML patients with complete remission (CR)...
2023: Frontiers in Immunology
#3
JOURNAL ARTICLE
Etienne Masle-Farquhar, Yogesh Jeelall, Jacqueline White, Julia Bier, Elissa K Deenick, Robert Brink, Keisuke Horikawa, Christopher Carl Goodnow
INTRODUCTION: Germline CARD11 gain-of-function (GOF) mutations cause B cell Expansion with NF-κB and T cell Anergy (BENTA) disease, whilst somatic GOF CARD11 mutations recur in diffuse large B cell lymphoma (DLBCL) and in up to 30% of the peripheral T cell lymphomas (PTCL) adult T cell leukemia/lymphoma (ATL), cutaneous T cell lymphoma (CTCL) and Sezary Syndrome. Despite their frequent acquisition by PTCL, the T cell-intrinsic effects of CARD11 GOF mutations are poorly understood...
2023: Frontiers in Immunology
#4
JOURNAL ARTICLE
Xin Hua, Qi-Wei Zhu, Yi-Nuan Zhang, Lu Cao, Meng-Di Wang, Yun-Sheng Gao, Jia-Yi Chen
BACKGROUND: Recent studies have shown that ovarian aging is strongly associated with the risk of breast cancer, however, its prognostic impact on breast cancer is not yet fully understood. In this study, we performed a multicohort genetic analysis to explore its prognostic value and biological features in breast cancer. METHODS: The gene expression and clinicopathological data of 3366 patients from the The Cancer Genome Atlas (TCGA) cohort, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort and the GSE86166 cohort were analyzed...
2023: Frontiers in Immunology
#5
JOURNAL ARTICLE
Hakjun Hyun, A-Yeung Jang, Heedo Park, Jung Yeon Heo, Yu Bin Seo, Eliel Nham, Jin Gu Yoon, Hye Seong, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Soo-Young Yoon, Jong Hyeon Seok, Jineui Kim, Man-Seong Park, Joon Young Song
BACKGROUND: Whether or not a single-dose Ad26.COV2.S prime and boost vaccination induces sufficient immunity is unclear. Concerns about the increased risk of breakthrough infections in the Ad26.COV2.S-primed population have also been raised. METHODS: A prospective cohort study was conducted. Participants included healthy adults who were Ad26.COV2.S primed and scheduled to receive a booster vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. The IgG anti-receptor binding domain (RBD) antibody titers, neutralizing antibody (NAb) titers (against wild type [WT] and Omicron [BA...
2023: Frontiers in Immunology
#6
JOURNAL ARTICLE
Per Ljungman, Gloria Tridello, Jose Luis Piñana, Fabio Ciceri, Henrik Sengeloev, Alexander Kulagin, Stephan Mielke, Zeynep Arzu Yegin, Matthew Collin, Sigrun Einardottir, Sophie Ducastelle Lepretre, Johan Maertens, Antonio Campos, Elisabetta Metafuni, Herbert Pichler, Frantisek Folber, Carlos Solano, Emma Nicholson, Meltem Kurt Yüksel, Kristina Carlson, Beatriz Aguado, Caroline Besley, Jenny Byrne, Immaculada Heras, Fiona Dignan, Nicolaus Kröger, Christine Robin, Anjum Khan, Stig Lenhoff, Anna Grassi, Veronika Dobsinska, Nuno Miranda, Maria-Jose Jimenez, Ipek Yonal-Hindilerden, Keith Wilson, Dina Averbuch, Simone Cesaro, Alienor Xhaard, Nina Knelange, Jan Styczynski, Malgorzata Mikulska, Rafael de la Camara
INTRODUCTION: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. METHODS: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. RESULTS: The median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19...
2023: Frontiers in Immunology
#7
Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi
BACKGROUND: Cancer is concerning owing to its high mortality rate. Consequently, methods of prolonging the life of patients with cancer have become the primary focus of attention research. In recent years, immune checkpoint inhibitors (ICIs) have achieved good clinical efficacy as antitumor drugs; however, their severe adverse effects have made their use challenging. In order to clarify the predictors of adverse effects, scientists have conducted a series of studies. Blood counts can potentially monitor risk factors associated with the occurrence of immune-related adverse events (irAEs)...
2023: Frontiers in Immunology
#8
JOURNAL ARTICLE
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
INTRODUCTION: Bladder cancer (BLCA) is a highly malignant tumor of the urinary system, but the prognosis and survival rates have little improvement based on current therapeutic strategy. Immune checkpoint inhibitors (ICIs) therapy revolutionized the treatment of BLCA, but the clinical application of ICIs is limited by low response rate. Oxaliplatin (OXP), a second line chemotherapy drug for BLCA, may reshape the tumor immune microenvironment (TIME) via recruiting immune cells. Here, we conducted the study of oxaliplatin combined with anti-PD-1 inhibitor in BLCA mice models...
2023: Frontiers in Immunology
#9
JOURNAL ARTICLE
Angela Flavia Serpico, Caterina Pisauro, Domenico Grieco
Taxanes are Microtubule-Targeting Agents (MTAs) that exert potent anticancer activity by directly killing cancer cells. However, recent evidence suggests that they may also stimulate inflammation and anticancer adaptive immunity and that these actions strongly contribute to their therapeutic efficacy. Details on how Taxanes may modulate inflammation and anticancer immunity are, nevertheless, still missing. We show here that at very low doses the Taxane Paclitaxel (Pxl) indeed induces a potent proinflammatory response in various cancer cell types in a cyclic GMP-AMP (cGAMP) synthase (cGAS)- and Stimulator of Interferon Genes (STING)-dependent manner, leading to interferon (IFN) signaling...
2023: Frontiers in Immunology
#10
JOURNAL ARTICLE
Irina Larionova, Artem Kiselev, Elena Kazakova, Tengfei Liu, Marina Patysheva, Pavel Iamshchikov, Quan Liu, Dieuwertje M Mossel, Vladimir Riabov, Militsa Rakina, Alexey Sergushichev, Natalia Bezgodova, Sergei Vtorushin, Nikolai Litviakov, Evgeny Denisov, Philipp Koshkin, Denis Pyankov, Matvei Tsyganov, Marina Ibragimova, Nadezhda Cherdyntseva, Julia Kzhyshkowska
INTRODUCTION: Tumor resistance to chemotherapy and metastatic relapse account for more than 90% of cancer specific mortality. Tumor-associated macrophages (TAMs) can process chemotherapeutic agents and impair their action. Little is known about the direct effects of chemotherapy on TAMs. METHODS: The effect of chemotherapeutic platinum agent cisplatin was assessed in the model system of human ex vivo TAMs. Whole-transcriptome sequencing for paired TAMs stimulated and not stimulated by cisplatin was analysed by NGS...
2023: Frontiers in Immunology
#11
JOURNAL ARTICLE
Zaigham Abbas Rizvi, Prabhakar Babele, Upasna Madan, Srikanth Sadhu, Manas Ranjan Tripathy, Sandeep Goswami, Shailendra Mani, Madhu Dikshit, Amit Awasthi
Cytokine release syndrome (CRS) due to severe acute respiratory coronavirus-2 (SARS-CoV-2) infection leads to life-threatening pneumonia which has been associated with coronavirus disease (COVID-19) pathologies. Centuries-old Asian traditional medicines such as Withania somnifera (L.) Dunal (WS) and Tinospora cordifolia ( Willd.) Miers (TC) possess potent immunomodulatory effects and were used by the AYUSH ministry, in India during the COVID-19 pandemic. In the present study, we investigated WS and TC's anti-viral and immunomodulatory efficacy at the human equivalent doses using suitable in vitro and in vivo models...
2023: Frontiers in Immunology
#12
JOURNAL ARTICLE
Peng Song, Ke Cao, Yonghuan Mao, Shichao Ai, Feng Sun, Qiongyuan Hu, Song Liu, Meng Wang, Xiaofeng Lu, Wenxian Guan, Xiaofei Shen
INTRODUCTION: Innate lymphoid cells (ILCs) are key components of the immune system, yet the similarity and distinction of the properties across tissues under homeostasis, inflammation and tumor process remain elusive. METHODS: Here we performed integrative inference of ILCs to reveal their transcriptional profiles and heterogeneity from single-cell genomics. We collected a large number of ILCs from human six different tissues which can represent unique immune niches (circulation, lymphoid tissue, normal and inflamed mucosa, tumor microenvironment), to systematically address the transcriptional imprinting...
2023: Frontiers in Immunology
#13
Izabella Owsianka, Agnieszka Pac, Estera Jachowicz, Karolina Gutkowska, Wiktor Szczuciński, Barbara Maziarz, Elżbieta Sochacka-Tatara, Piotr Heczko, Wojciech Sydor, Barbara Żółtowska, Jadwiga Wójkowska-Mach
[This corrects the article DOI: 10.3389/fimmu.2022.1071204.].
2023: Frontiers in Immunology
#14
JOURNAL ARTICLE
Xu-Zhe Zhang, Xian-Li Chen, Ting-Ting Tang, Si Zhang, Qin-Lin Li, Ni Xia, Shao-Fang Nie, Min Zhang, Zheng-Feng Zhu, Zi-Hua Zhou, Nian-Guo Dong, Xiang Cheng
BACKGROUND: Epicardial adipose tissue (EAT) acts as an active immune organ and plays a critical role in the pathogenesis of heart failure (HF). However, the characteristics of immune cells in EAT of HF patients have rarely been elucidated. METHODS: To identify key immune cells in EAT, an integrated bioinformatics analysis was performed on public datasets. EAT samples with paired subcutaneous adipose tissue (SAT), heart, and peripheral blood samples from HF patients were collected in validation experiments...
2023: Frontiers in Immunology
#15
EDITORIAL
Jiang Pi, Ling Shen, Hongbo Shen
No abstract text is available yet for this article.
2023: Frontiers in Immunology
#16
JOURNAL ARTICLE
Cejun Yang, Wendi Wang, Sang Li, Zhengkang Qiao, Xiaoqian Ma, Min Yang, Juan Zhang, Lu Cao, Shanhu Yao, Zhe Yang, Wei Wang
INSTRUCTION: Ulcerative colitis (UC) can cause a variety of immune-mediated intestinal dysfunctions and is a significant model of inflammatory bowel disease (IBD). Colorectal cancer (CRC) mostly occurs in patients with ulcerative colitis. Cuproptosis is a type of procedural death that is associated with different types of diseases to various degrees. METHODS: We used a combination of bioinformatic prediction and experimental verification to study the correlation between copper poisoning and UC...
2023: Frontiers in Immunology
#17
JOURNAL ARTICLE
Rafael F Guilherme, José Bruno N F Silva, Ingrid Waclawiack, Vanderlei S Fraga-Junior, Thaís O Nogueira, Cyntia Pecli, Carlla A Araújo-Silva, Nathalia S Magalhães, Felipe S Lemos, Carlos A Bulant, Pablo J Blanco, Rafaela Serra, Erik Svensjö, Júlio Scharfstein, João A Moraes, Claudio Canetti, Claudia F Benjamim
INTRODUCTION: Pulmonary fibrosis is a destructive, progressive disease that dramatically reduces life quality of patients, ultimately leading to death. Therapeutic regimens for pulmonary fibrosis have shown limited benefits, hence justifying the efforts to evaluate the outcome of alternative treatments. METHODS: Using a mouse model of bleomycin (BLM)-induced lung fibrosis, in the current work we asked whether treatment with pro-resolution molecules, such as pro-resolving lipid mediators (SPMs) could ameliorate pulmonary fibrosis...
2023: Frontiers in Immunology
#18
REVIEW
Zhangyan Guo, Rui Zhang, An-Gang Yang, Guoxu Zheng
Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors...
2023: Frontiers in Immunology
#19
JOURNAL ARTICLE
Albert Amberger, Johanna Pertoll, Pia Traunfellner, Ines Kapferer-Seebacher, Heribert Stoiber, Lars Klimaschewski, Nicole Thielens, Christine Gaboriaud, Johannes Zschocke
Periodontal Ehlers-Danlos syndrome (pEDS) is an autosomal dominant disorder characterized by early-onset periodontitis leading to premature loss of teeth, lack of attached gingiva and thin and fragile gums leading to gingival recession. Connective tissue abnormalities of pEDS typically include easy bruising, pretibial plaques, distal joint hypermobility, hoarse voice, and less commonly manifestations such as organ or vessel rupture. pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex...
2023: Frontiers in Immunology
#20
JOURNAL ARTICLE
Joselyn Cruz Cruz, Kristen C Allison, Lauren S Page, Alexis J Jenkins, Xiaodong Wang, H Shelton Earp, Stephen V Frye, Douglas K Graham, Michael R Verneris, Alisa B Lee-Sherick
BACKGROUND: Previous studies show that the spleen and bone marrow can serve as leukemia microenvironments in which macrophages play a significant role in immune evasion and chemoresistance. We hypothesized that the macrophage driven tolerogenic process of efferocytosis is a major contributor to the immunosuppressive leukemia microenvironment and that this was driven by aberrant phosphatidylserine expression from cell turnover and cell membrane dysregulation. METHODS: Since MerTK is the prototypic efferocytosis receptor, we assessed whether the MerTK inhibitor MRX2843, which is currently in clinical trials, would reverse immune evasion and enhance immune-mediated clearance of leukemia cells...
2023: Frontiers in Immunology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
